Paul M. Meister
Paul M. Meister's purchase track record
Paul M. Meister has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/5/2026 | APTV | $5.00M | pending | pending | — |
| 8/10/2022 | QTRX | $2.00M | +10.4% | +66.0% | -2.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
AMRX Gains Fair Value Bump After Analyst Support for New Launches. Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Versigent Releases Q2 2026 Earnings Call Transcript. Versigent PLC has published the transcript of its Q2 2026 earnings call. The release gives investors access to management’s discussion of the quarter’s performance and outlook. The transcript is available through Benzinga and provides context for the company’s recent financial results.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Quanterix Highlights Spatial Biology Innovation at ESSB 2026. Quanterix announced it met its spatial biology content innovation commitments during the ESSB 2026 event. The company showcased new tools and data sets that support advanced spatial analysis. This demonstrates progress in its product roadmap and may strengthen its position in the spatial biology market.
Transaction History
| APTV | ▲ Buy | Open Market | 105,631 | $5.0M | 8/5/2026 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 48,747 | — | 5/7/2026 | View on chart |
| APTV | ▲ Buy | Grant | 6,344 | $0 | 4/29/2026 | View on chart |
| APTV | ▼ Sell | Tax Withholding | 590 | $35K | 4/28/2026 | View on chart |
| VGNT | ▲ Buy | Grant | 5,168 | $0 | 4/22/2026 | View on chart |
| QTRX | ▲ Buy | Grant | 3,974 | $0 | 1/2/2026 | View on chart |
| QTRX | ▲ Buy | Grant | 2,242 | $15K | 7/1/2025 | View on chart |
| APTV | ▼ Sell | Gift | 19,181 | $0 | 5/14/2025 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 56,361 | — | 5/5/2025 | View on chart |
| APTV | ▲ Buy | Grant | 6,941 | $0 | 4/23/2025 | View on chart |
| APTV | ▼ Sell | Tax Withholding | 231 | $12K | 4/22/2025 | View on chart |
| QTRX | ▲ Buy | Grant | 2,479 | $17K | 4/1/2025 | View on chart |
| QTRX | ▲ Buy | Grant | 7,435 | $0 | 1/2/2025 | View on chart |
| QTRX | ▲ Buy | Grant | 1,394 | $15K | 1/2/2025 | View on chart |
| QTRX | ▲ Buy | Grant | 1,200 | $15K | 10/1/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 1,182 | $15K | 7/1/2024 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 107,034 | — | 5/10/2024 | View on chart |
| APTV | ▲ Buy | Grant | 5,183 | $0 | 4/25/2024 | View on chart |
| APTV | ▼ Sell | Tax Withholding | 337 | $24K | 4/23/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 630 | $15K | 4/1/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 2,947 | $0 | 1/2/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 552 | $15K | 1/2/2024 | View on chart |
| QTRX | ▲ Buy | Grant | 561 | $15K | 10/2/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 687 | $15K | 7/3/2023 | View on chart |
| QTRX | ▲ Buy | Option Exercise | 23,335 | $67K | 6/7/2023 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 112,179 | — | 5/10/2023 | View on chart |
| APTV | ▲ Buy | Grant | 3,598 | $0 | 4/26/2023 | View on chart |
| APTV | ▼ Sell | Tax Withholding | 394 | $40K | 4/25/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 1,344 | $15K | 4/3/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 1,166 | $15K | 1/3/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 8,083 | $0 | 1/3/2023 | View on chart |
| QTRX | ▲ Buy | Grant | 1,431 | $15K | 10/3/2022 | View on chart |
| QTRX | ▲ Buy | Open Market | 186,347 | $1.6M | 8/10/2022 | View on chart |
| QTRX | ▲ Buy | Open Market | 47,957 | $413K | 8/10/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 893 | $15K | 7/1/2022 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 52,677 | — | 5/8/2022 | View on chart |
| APTV | ▲ Buy | Grant | 3,568 | $0 | 4/27/2022 | View on chart |
| APTV | ▼ Sell | Tax Withholding | 187 | $19K | 4/26/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 492 | $15K | 4/1/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 324 | $14K | 1/3/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 2,668 | $0 | 1/3/2022 | View on chart |
| QTRX | ▲ Buy | Grant | 269 | $14K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Aptiv Leaves FTSE All-World Index Amid Mixed Market Performance
Aptiv was removed from the FTSE All-World Index, a development that may impact passive fund flows. While the company remains a key player in the growing EV connector market, recent stock performance has lagged broader market trends. Analysts continue to debate its valuation, with some viewing it as undervalued despite its current trading position.
Aptiv Leaves FTSE All-World Index Amid Mixed Market Performance. Aptiv was removed from the FTSE All-World Index, a development that may impact passive fund flows. While the company remains a key player in the growing EV connector market, recent stock performance has lagged broader market trends. Analysts continue to debate its valuation, with some viewing it as undervalued despite its current trading position.